Investment Thesis
STERIS demonstrates fortress-like financial health with exceptional free cash flow generation ($972.4M, 16.4% margin) and fortress balance sheet (Debt/Equity 0.25x), supported by solid 8.7% revenue growth in the defensive surgical supplies sector. However, flat net income growth (-0.4% YoY) despite revenue expansion reveals concerning margin compression, with EPS growth of 27.9% artificially driven by share buybacks rather than operational improvement.
Strengths
- Exceptional free cash flow generation at 124% of net income, providing financial flexibility and safety margin
- Conservative capital structure with 0.25x Debt/Equity ratio and 36.3x interest coverage, offering acquisition optionality
- Solid revenue growth of 8.7% YoY in stable, defensive surgical supplies and orthopedic devices sector
- Strong liquidity with 2.09x current ratio and 1.54x quick ratio indicating robust operational flexibility
- Healthy profitability across all levels: 44.2% gross margin, 18.6% operating margin, 13.2% net margin
Risks
- Net income essentially flat (-0.4%) despite 8.7% revenue growth signals significant margin compression and operational headwinds
- EPS growth of 27.9% driven primarily by share buybacks rather than organic operational improvements, indicating earnings are artificial
- Medical device sector exposure to regulatory pressures, reimbursement headwinds, and competitive intensity from larger diversified peers
- Minimal insider activity (1 Form 4 filing in 90 days) suggests limited conviction from management regarding company prospects
Key Metrics to Watch
- Operating margin trend—critical to determine if 18.6% can be sustained or will face further compression
- Free cash flow conversion ratio—monitor sustainability of exceptional 16.4% FCF margin
- Revenue organic growth rate—need to separate growth by pricing vs. volume to assess pricing power
Financial Metrics
Revenue
5.9B
Net Income
782.3M
EPS (Diluted)
$7.93
Free Cash Flow
972.4M
Total Assets
10.7B
Cash
439.6M
Profitability Ratios
Gross Margin
44.2%
Operating Margin
18.6%
Net Margin
13.2%
ROE
10.9%
ROA
7.3%
FCF Margin
16.4%
Balance Sheet & Liquidity
Current Ratio
2.09x
Quick Ratio
1.54x
Debt/Equity
0.25x
Debt/Assets
33.0%
Interest Coverage
36.26x
Long-term Debt
1.8B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-30T07:13:31.234150 |
Data as of: 2026-03-31 |
Powered by Claude AI